Atlantis Ventures

Atlantis Ventures is the Munich-based investment vehicle of a German family office that writes pre-seed and seed checks into European technology and software companies. Healthcare is not a stated theme, which is the most important thing to know up front. Physician founders should consider Atlantis only if their company is fundamentally a software business that happens to operate in or near healthcare, not a clinical, regulated, or device-driven venture.

The thesis is software-first and European, with a clear bias toward founders building horizontal infrastructure, vertical SaaS, or applied-AI products. The fund operates as a co-investor rather than a lead, which means it expects another institutional investor to set terms and do the bulk of diligence. That structure makes Atlantis a useful round-filler for founders who already have a credible lead but want additional European capital and a long-term family-office partner who is not optimizing for a fund-cycle exit. The fund does not publish portfolio companies on its public site, so any specific company-level pattern matching will require a direct conversation.

Check sizes sit in the 250 thousand to 1 million dollar range, which is consistent with a co-investor profile at pre-seed and seed. Geography spans Germany, the United Kingdom, Sweden, and Denmark, with a Munich anchor that suggests a particular ease with DACH-region founders. The fund is comfortable with companies that have not yet generated meaningful revenue, but expects a clear product thesis and a credible founding team.

Finn Theyntzler is the named founder of the vehicle and the primary point of contact. Decisions appear to run through him directly, which keeps the process compact and avoids the committee dynamics of larger institutional funds.

Approach Atlantis when you are a European software founder with a lead investor already circling, a working product, and a need for additional capital from a patient family-office source. Healthcare-adjacent software is plausible if the software story is the dominant one. Pure clinical AI, medical devices, regulated digital therapeutics, and bio plays are unlikely to find a home here. The most reliable path in is a warm introduction from another European seed fund, an existing portfolio founder, or a Munich-based operator who knows Finn directly. Cold outreach is unlikely to land given the family-office structure and the absence of a public application channel. Time the conversation to begin once you have the lead conversation moving forward, because Atlantis will want to see term-sheet momentum before committing rather than serving as the catalytic first check.